Michele Andrasik1, Doug Grove2, Gail Broder3, Hyman Scott4, Mary Allen5, Shelly Karuna6. 1. Fred Hutch HIV Vaccine Trials Network, United States. Electronic address: mandrasik@fredhutch.org. 2. Fred Hutch, Statistical Center for HIV/AIDS Research and Prevention, United States. Electronic address: dgrove@scharp.org. 3. Fred Hutch HIV Vaccine Trials Network, United States. Electronic address: gbroder@fredhutch.org. 4. Bridge HIV, San Francisco Department of Public Health, United States. Electronic address: hyman.scott@sfdph.org. 5. NIH/NIAID, United States. Electronic address: MAllen@niaid.nih.gov. 6. Fred Hutch HIV Vaccine Trials Network, United States. Electronic address: mkaruna@fredhutch.org.
Abstract
BACKGROUND: HIV disproportionately impacts transgender populations globally, creating challenges to inclusion in trials requiring low HIV risk profiles (LHRP) for acquisition. Our knowledge of transgender individuals with LHRP is limited. We conducted an analysis of transgender and cisgender individuals in HVTN trials enrolling individuals with LHRP. METHODS: We analyzed data from 694 participants enrolled in the phase 1-2a HVTN trials in the US and Peru from 2009 to 2014 that included individuals who reported gender identity (GI) differing from assigned birth sex (transgender [TG]), and compared them with those who reported a congruent GI (cisgender [CG]). RESULTS: 681 participants (98%) were CG and 13 (2%) were TG. Mean age was 25 years. 16% were Hispanic and most (69%) were White. Reasons for enrolling included to help find an effective vaccine (TG 100%; CG 98%) and help their community (TG 100%; CG 96%). Significant differences by GI were observed in reported pre-existing conditions (p = 0.004); however, approximately 10% of pre-existing conditions reported by TG were GI-related (e.g., gender dysphoria). Significant differences were observed in hormone therapy use (p < 0.001) and mental health medications (p = 0.007). Retention was excellent with 2.1% missed visits and no discontinuations of vaccination for TG and 3% missed visits and 7.1% discontinuations among CG. There was no statistically significant difference in HIV incidence. CONCLUSIONS: Primary reasons for participation were altruistic for all participants. Comparable to CG counterparts, TG participants maintained LHRP, followed trial procedures, and had high retention, facilitating meaningful early phase HIV preventive vaccine trial contributions.
BACKGROUND: HIV disproportionately impacts transgender populations globally, creating challenges to inclusion in trials requiring low HIV risk profiles (LHRP) for acquisition. Our knowledge of transgender individuals with LHRP is limited. We conducted an analysis of transgender and cisgender individuals in HVTN trials enrolling individuals with LHRP. METHODS: We analyzed data from 694 participants enrolled in the phase 1-2a HVTN trials in the US and Peru from 2009 to 2014 that included individuals who reported gender identity (GI) differing from assigned birth sex (transgender [TG]), and compared them with those who reported a congruent GI (cisgender [CG]). RESULTS: 681 participants (98%) were CG and 13 (2%) were TG. Mean age was 25 years. 16% were Hispanic and most (69%) were White. Reasons for enrolling included to help find an effective vaccine (TG 100%; CG 98%) and help their community (TG 100%; CG 96%). Significant differences by GI were observed in reported pre-existing conditions (p = 0.004); however, approximately 10% of pre-existing conditions reported by TG were GI-related (e.g., gender dysphoria). Significant differences were observed in hormone therapy use (p < 0.001) and mental health medications (p = 0.007). Retention was excellent with 2.1% missed visits and no discontinuations of vaccination for TG and 3% missed visits and 7.1% discontinuations among CG. There was no statistically significant difference in HIV incidence. CONCLUSIONS: Primary reasons for participation were altruistic for all participants. Comparable to CG counterparts, TG participants maintained LHRP, followed trial procedures, and had high retention, facilitating meaningful early phase HIV preventive vaccine trial contributions.
Authors: Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden Journal: N Engl J Med Date: 2010-11-23 Impact factor: 91.245
Authors: Eva Van Caenegem; Katrien Wierckx; Els Elaut; Ann Buysse; Alexis Dewaele; Filip Van Nieuwerburgh; Griet De Cuypere; Guy T'Sjoen Journal: Arch Sex Behav Date: 2015-01-15
Authors: Sally L Hodder; Jessica Justman; James P Hughes; Jing Wang; Danielle F Haley; Adaora A Adimora; Carlos Del Rio; Carol E Golin; Irene Kuo; Anne Rompalo; Lydia Soto-Torres; Sharon B Mannheimer; Letanya Johnson-Lewis; Susan H Eshleman; Wafaa M El-Sadr Journal: Ann Intern Med Date: 2013-01-01 Impact factor: 25.391
Authors: Scott M Hammer; Magdalena E Sobieszczyk; Holly Janes; Shelly T Karuna; Mark J Mulligan; Doug Grove; Beryl A Koblin; Susan P Buchbinder; Michael C Keefer; Georgia D Tomaras; Nicole Frahm; John Hural; Chuka Anude; Barney S Graham; Mary E Enama; Elizabeth Adams; Edwin DeJesus; Richard M Novak; Ian Frank; Carter Bentley; Shelly Ramirez; Rong Fu; Richard A Koup; John R Mascola; Gary J Nabel; David C Montefiori; James Kublin; M Juliana McElrath; Lawrence Corey; Peter B Gilbert Journal: N Engl J Med Date: 2013-10-07 Impact factor: 91.245
Authors: Jeffrey H Herbst; Elizabeth D Jacobs; Teresa J Finlayson; Vel S McKleroy; Mary Spink Neumann; Nicole Crepaz Journal: AIDS Behav Date: 2007-08-13
Authors: Sari L Reisner; Kerith J Conron; Laura Anatale Tardiff; Stephanie Jarvi; Allegra R Gordon; S Bryn Austin Journal: BMC Public Health Date: 2014-11-26 Impact factor: 3.295
Authors: Michele P Andrasik; Gail B Broder; Stephaun E Wallace; Richa Chaturvedi; Nelson L Michael; Sally Bock; Chris Beyrer; Linda Oseso; Jasmin Aina; Jonathan Lucas; David R Wilson; James G Kublin; George A Mensah Journal: PLoS One Date: 2021-10-19 Impact factor: 3.752